Find a Clinical Trial

An Observational Study of Patients Receiving T-DXd for Treatment of HER2+, and HER2-low Unresectable and/​or Metastatic Breast Cancer

DESTINY BREAST - RESPOND: A multi-center, multi-country prospective observational study of patients initiating T-DXd in the first or second treatment line for HER2+, and HER2-low unresectable and/or metastatic breast cancer (D9673R00025)

16+

Learn more

A Long COVID-19 Observational Pilot Study Using Wearable Devices

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

18+

Learn more

Period Kits

Development and Evaluation of “Period Kits” for Adolescents with Intellectual and Cognitive Disabilities

0-17

Learn more

Discovery

Discovery Approach to Ocular Hypertension

No minimum age

Learn more

wtATTR-CIAP Burden Study

Dissecting the neuropathic burden in wtATTR: its role in staging and burden of disease, and in differentiating from chronic idiopathic axonal polyneuropathy

18+

Learn more

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

EA1211, Interim FDG-PET/CT for PreDIcting REsponse of HER2+ Breast Cancer to Neoadjuvant Therapy: DIRECT trial

18+

Learn more

Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery

EA3132 - Phase II Randomized Trial of Radiotherapy with or without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing

18+

Learn more

EA3191

EA3191 - A Phase II Randomized Trial of Adjuvant Therapy with Pembrolizumab after Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma with High Risk Features

18-79

Learn more

EAQ202

EAQ202, Improving Adolescent and Young Adult Self-Reported Data in ECOG-ACRIN Trials

18-39

Learn more

Effects of BCR-ABL tyrosine kinase inhibitors on platelets and white blood cells

Effects of BCR-ABL tyrosine kinase inhibitors on platelets and white blood cells

18+

Learn more